Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI.
Two novel stem cell factor (SCF) dependent human mast cell lines, designated LAD 1 and 2, were established from bone marrow aspirates from a patient with mast cell sarcoma/leukemia. LAD 1 and 2 cells have the ultrastructural features of human mast cells, and express FcepsilonRI, CD4, 9, 13, 14, 22, 31, 32, 45, 64, 71, 103, 117, 132, CXCR4 (CD184), CCR5 (CD195); and intracytoplasmic histamine, tryptase and chymase. LAD 1 and 2 do not exhibit activating mutations at codon 816 of c-kit. Both LAD 1 and 2 release beta-hexosaminidase following FcepsilonRI or FcgammaRI aggregation. The availability of these cell lines offers an unparalleled circumstance to examine the biology of human mast cells.
Kirshenbaum
Arnold S
AS
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1881, USA.
Akin
Cem
C
Wu
Yalin
Y
Rottem
Menachem
M
Goff
Julie P
JP
Beaven
Michael A
MA
Rao
V Koneti
VK
Metcalfe
Dean D
DD
D000328:Adult; D001854:Bone Marrow Cells / Q000473:pathology; D002455:Cell Division; D002460:Cell Line; D019281:Dimerization; D006801:Humans; D016130:Immunophenotyping; D007621:Karyotyping; D007946:Leukemia, Mast-Cell / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D008297:Male; D008407:Mast Cells / Q000201:enzymology / Q000473:pathology*; D012515:Mast-Cell Sarcoma / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D009154:Mutation; D017455:Receptors, IgE / Q000378:metabolism; D017452:Receptors, IgG / Q000378:metabolism; D019089:Stem Cell Factor / Q000494:pharmacology
D017455:Receptors, IgE; D017452:Receptors, IgG; D019089:Stem Cell Factor